Precision Medicine Switch in Lipid Metabolism, ANGPTL3: Baseline Triglycerides Determine Therapeutic Efficacy
##1. Paradox of ANGPTL3 Deficiency and ASCVD Prevention ANGPTL3 (Angiopoietin-like protein 3) is a hepatic protein that regulates systemic lipid metabolism. Individuals with genetic deficiency of ANGPTL3 exhibit a pan‑hypolipidemic phenotype characterized by low triglycerides, LDL‑C, and HDL‑C, which confers strong protection against atherosclerotic cardiovascular disease (ASCVD). This genetic evidence has propelled ANGPTL3 to the forefront as one of the most attractive targets for dyslipidemia therapy.
##2. Competition Across Modalities: From mAbs to CRISPR Gene Editing Human efforts to inhibit ANGPTL3 span the full spectrum of genetic and molecular strategies. Starting with the monoclonal antibody Evinacumab, ASO‑based Vupanorsen, and siRNA‑based Zodasiran and Solbinsiran have entered clinical development. More recently, CRISPR‑based approaches such as VERVE‑201 and CTX310 have been introduced, initiating attempts to permanently remodel lipid profiles with a single administration.
##3. Context‑Dependent Biology: Baseline Triglycerides Determine LDL‑C Reduction The most important finding from clinical trials is that the efficacy of ANGPTL3 inhibitors exhibits ‘context dependence’ on a patient’s baseline lipid profile. Specifically, patients with higher baseline triglyceride levels experience a more pronounced LDL‑C reduction. This suggests that ANGPTL3 inhibition is not merely a cholesterol‑lowering tool but operates through a precise mechanism that modulates triglyceride‑rich lipoproteins (TRL) and remnant cholesterol.
##4. Why it Matters: Establishing a Standard for Precision Lipid Therapy and the Future of Gene Editing This work is important because it demonstrates that dyslipidemia treatment must evolve from a one‑size‑fits‑all approach to a targeting strategy based on individual lipid profiles. Identifying ANGPTL3 as the optimal target for high‑risk patients with hypertriglyceridemia can improve the success rate of drug development. Moreover, the maturation of gene‑editing technologies is poised to shift the chronic‑disease management paradigm—from lifelong medication to a single‑dose curative intervention.
INTRODUCTION: Angiopoietin-like protein 3 (ANGPTL3) has emerged over the past decade as one of the most intriguing therapeutic targets in lipid metabolism. AREAS COVERED: Genetic deficiency of ANGPTL3 in humans produces a striking pan-hypolipidemic phenotype, with reductions in triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), accompanied by protection from atherosclerotic cardiovascular disease (ASCVD). These observations rapidly catalyzed the development of pharmacologic strategies to inhibit ANGPTL3 using monoclonal antibodies (e.g. evinacumab), antisense oligonucleotides (e.g. vupanorsen), small interfering ribonucleic acid (e.g. zodasiran and solbinsiran), and most recently genome-editing approaches (e.g. VERVE-201 and CTX310). However, clinical experience has revealed a more complex and context-dependent biology than initially anticipated. EXPERT OPINION: This review examines whether ANGPTL3 should be considered a clinically meaningful cholesterol-lowering target, as exemplified by efficacy of ANGPTL3 inhibition in homozygous familial hypercholesterolemia, or whether its principal therapeutic value lies in modulation of triglyceride-rich lipoproteins and remnant cholesterol, with secondary effects on LDL-C. The degree of hypertriglyceridemia in the patient's baseline lipid profile appears to be an important determinant of drug response. Drawing on genetic, mechanistic, and clinical trial data, the promise and limitations of ANGPTL3 inhibition are considered and its potential place in future lipid-lowering strategies is outlined. A liver protein called ANGPTL3 has become one of the most promising drug targets for new cholesterol-lowering treatments. People born with a natural deficiency of this protein have unusually low levels of all blood fats – including triglycerides and both ‘bad’ (LDL) and ‘good’ (HDL) cholesterol – and are largely protected from heart disease. This sparked intense interest in de
This dataset quantitatively illustrates how genetic evidence translates into drug development (Genetic‑to‑Clinic) and how patient‑specific biological context determines drug responsiveness. It serves as an essential reference for designing clinical trials of next‑generation lipid modulators and for training AI models that predict patient responses.